MedMira Wins $4.2 Million U.S. Army Contract to Commercialize Rapid Triple Test

Informations

• Publié par: medmira-inc
• Nombre de lectures: 35
• Langue: English

Extrait

MedMira Wins $4.2 Million U.S. Army Contract

to Commercialize Rapid Triple Test

PR Newswire

HALIFAX, Nova Scotia, July 3, 2012

HALIFAX, Nova Scotia

,

July 3, 2012

/PRNewswire/ --

Under a US Army contract valued at

USD$4.2 million

,

MedMira will develop and commercialize this multiple

rapid test which detects HIV, Hepatitis B and C

simultaneously in 3 minutes from a single drop of

blood. (CNW Group/MEDMIRA INC.)

MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic

technology and solutions, announced today that it has been awarded a U.S.

Army Medical Research Acquisition Activity (USAMRAA) contract to develop and

commercialize a rapid test capable of simultaneous detection of HIV and

Hepatitis B and C.

The contract, awarded through a competitive bid process, involves a two-year

base period and a 10-month option with a value of

USD$4,266,144

, if all options

are exercised. MedMira presented its technology and multiple rapid test, which

met the U.S. Army's advanced technology readiness level requirements. The

Multiplo Rapid HBV/HIV/HCV Antibody Test resulting from this contract award

will be deployed on the frontlines of military healthcare for use in emergency

screening for transfusion transmitted diseases where no FDA approved donor

screening tests are available. The military could also put the test to use during

pre and post deployment screenings and civilian disaster relief efforts.

"We are thrilled to receive this new contract from USAMRAA for the

development and commercialization of our Multiplo test. This contract award

demonstrates the excellent fit between MedMira's technology and products and

military requirements. We have built a lasting relationship with the U.S. Army,

delivering advanced diagnostic solutions that reduce the need for militaries to

undertake ground-up development work," said Hermes Chan, CEO, MedMira

Inc. "MedMira's technology and products are elegantly simple, portable, fast,

and high quality. All of these attributes are mission critical in deploying

diagnostic healthcare solutions on the frontlines of military healthcare."

Chan continued, "Our team recently attended a conference focused on military

pre-hospital trauma management where we heard first hand of the need for a

multiple rapid HBV/HIV/HCV test from many of the leading experts, military

personnel, and medical professionals in this field."

Under contract number W81XWH-12-C-0151 the U.S. Army will fund all

development costs and associated fees in obtaining a U.S. Food and Drug

Administration (FDA) premarket approval (PMA) for this multiple rapid test. The

scope of work under this contract will see MedMira advance and fully

commercialize a multiple rapid test that will simultaneously detect three of the

most serious infectious diseases, namely HIV-1/2, Hepatitis B, and C antibodies

within three minutes using just a small drop of blood. Once approved, the

product will be supplied by MedMira directly to the U.S. Army and to other

customers throughout the world, both military and civilian, via the Company's

distribution network.

"

A multiplexed test for transfusion transmitted diseases provides an enabling

technology that will be used to mitigate risk in austere environments where

emergency blood collections are necessary to save lives of severely wounded

war fighters," said Colonel Richard Gonzales, Product Manager, U.S. Army

Medical Materiel Development Activity.

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid

diagnostics and technologies. The Company's tests provide hospitals, labs,

clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and

hepatitis C in just three minutes. The company's tests are sold under the

Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid flow-

through HIV test is the only one in the world to achieve regulatory approvals in

Canada

,

the United States

,

China

and the European Union. MedMira's corporate

offices and manufacturing facilities are located in

Halifax, Nova Scotia

, Canada.

For more information visit MedMira's website at http://www.medmira.com.

This news release contains forward-looking statements, including statements

relating to growth in the Company's business, earnings and profitability, and

trends in demand for the Company's products, which involve risk and

uncertainties and reflect the Company's current expectation regarding future

events including statements regarding possible future growth and new business

opportunities. Actual events could materially differ from those projected herein

and depend on a number of factors including, but not limited to, changing

market conditions, successful and timely completion of clinical studies,

uncertainties related to the regulatory approval process, establishment of

corporate alliances and other risks detailed from time to time in the company

quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that

term is defined in the policies of the TSX Venture Exchange) accepts

responsibility for the adequacy or accuracy of this release.

For further information:

MedMira Contact:

Andrea Young, Corporate Communications

Tel: [phone]

Email: [e-mail]